SCHEMBL25751558

SCHEMBL25751558

Cn1ccnc1S(=O)(=O)NC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.46
C1S P09871 1/20 0.42
ALDH1A1 P00352 4/20 0.38
PIK3C3 Q8NEB9 1/20 0.36
LPO P22079 1/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KAT5 Q92993 1/20 0.35
KAT8 Q9H7Z6 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
CHRM4 P08173 1/20 0.33
KIF18A Q8NI77 1/20 0.33
PARG Q86W56 1/20 0.33
NSD2 O96028 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24051973 0.79 MCL1 (0.46) MCL1C1SPIK3C3LPOSMN1; SMN2
SCHEMBL8230281 0.78 MCL1 (0.45) MCL1C1SPIK3C3LPOSMN1; SMN2
SCHEMBL24051971 0.76 MCL1 (0.44) MCL1C1SPIK3C3LPOSMN1; SMN2
SCHEMBL22951445 0.76 MCL1 (0.40) MCL1C1SALDH1A1PIK3C3LPO
SCHEMBL24051974 0.75 MCL1 (0.43) MCL1C1SALDH1A1PIK3C3LPO
SCHEMBL25753237 0.75 MCL1 (0.37) MCL1C1SALDH1A1PIK3C3KMT2A
SCHEMBL569909 0.72 LPO (0.43) MCL1C1SPIK3C3LPOMAPT
SCHEMBL5610393 0.71 LPO (0.41) MCL1C1SPIK3C3LPOKDM4E
SCHEMBL5610390 0.71 LPO (0.41) MCL1C1SPIK3C3LPOSMN1; SMN2
SCHEMBL604082 0.71 LPO (0.41) MCL1C1SPIK3C3LPOSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 MCL1 3867/4885C1S 1793/4885ALDH1A1 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.